Showing results (71-80 of 810) with videos related to

Sort By:
Pageof 81
Digestive Diseases (Basel, Switzerland)|June 22, 2011
Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patientsHanns-Ulrich Marschall, Martin Wagner, Gernot Zollner, et al.
The American Journal of Pathology|November 14, 2009
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblastsPeter Fickert, Andrea Fuchsbichler, Tarek Moustafa, et al.
Hepatology (Baltimore, Md.)|September 5, 2013
Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemiaPooja Jha, Thierry Claudel, Anna Baghdasaryan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 23, 2005
Hepatobiliary transporter expression in human hepatocellular carcinomaGernot Zollner, Martin Wagner, Peter Fickert, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|December 26, 2001
Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated miceGernot Zollner, Peter Fickert, Dagmar Silbert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 19, 2007
Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosisGernot Zollner, Martin Wagner, Peter Fickert, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 30, 2009
Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in miceJörg Jahnel, Peter Fickert, Cord Langner, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Alimentary Pharmacology & Therapeutics|August 28, 2025
Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune HepatitisLukas Burghart, Sonja Treiber, David Bauer, et al.
Digestion|September 12, 2012
Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humansHanns-Ulrich Marschall, Martin Wagner, Gernot Zollner, et al.
Pageof 81